Cargando…

Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process

The Six Sigma methodology has been widely implemented in industry, healthcare, and laboratory medicine since the mid-1980s. The performance of a process is evaluated by the sigma metric (SM), and 6 sigma represents world class performance, which implies that only 3.4 or less defects (or errors) per...

Descripción completa

Detalles Bibliográficos
Autores principales: Coskun, Abdurrahman, Ialongo, Cristiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Society of Medical Biochemistry and Laboratory Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999184/
https://www.ncbi.nlm.nih.gov/pubmed/32063732
http://dx.doi.org/10.11613/BM.2020.010901
_version_ 1783493938418548736
author Coskun, Abdurrahman
Ialongo, Cristiano
author_facet Coskun, Abdurrahman
Ialongo, Cristiano
author_sort Coskun, Abdurrahman
collection PubMed
description The Six Sigma methodology has been widely implemented in industry, healthcare, and laboratory medicine since the mid-1980s. The performance of a process is evaluated by the sigma metric (SM), and 6 sigma represents world class performance, which implies that only 3.4 or less defects (or errors) per million opportunities (DPMO) are expected to occur. However, statistically, 6 sigma corresponds to 0.002 DPMO rather than 3.4 DPMO. The reason for this difference is the introduction of a 1.5 standard deviation (SD) shift to account for the random variation of the process around its target. In contrast, a 1.5 SD shift should be taken into account for normally distributed data, such as the analytical phase of the total testing process; in practice, this shift has been included in all type of calculations related to SM including non-normally distributed data. This causes great deviation of the SM from the actual level. To ensure that the SM value accurately reflects process performance, we concluded that a 1.5 SD shift should be used where it is necessary and formally appropriate. Additionally, 1.5 SD shift should not be considered as a constant parameter automatically included in all calculations related to SM.
format Online
Article
Text
id pubmed-6999184
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Croatian Society of Medical Biochemistry and Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-69991842020-02-15 Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process Coskun, Abdurrahman Ialongo, Cristiano Biochem Med (Zagreb) Short Communication The Six Sigma methodology has been widely implemented in industry, healthcare, and laboratory medicine since the mid-1980s. The performance of a process is evaluated by the sigma metric (SM), and 6 sigma represents world class performance, which implies that only 3.4 or less defects (or errors) per million opportunities (DPMO) are expected to occur. However, statistically, 6 sigma corresponds to 0.002 DPMO rather than 3.4 DPMO. The reason for this difference is the introduction of a 1.5 standard deviation (SD) shift to account for the random variation of the process around its target. In contrast, a 1.5 SD shift should be taken into account for normally distributed data, such as the analytical phase of the total testing process; in practice, this shift has been included in all type of calculations related to SM including non-normally distributed data. This causes great deviation of the SM from the actual level. To ensure that the SM value accurately reflects process performance, we concluded that a 1.5 SD shift should be used where it is necessary and formally appropriate. Additionally, 1.5 SD shift should not be considered as a constant parameter automatically included in all calculations related to SM. Croatian Society of Medical Biochemistry and Laboratory Medicine 2020-02-15 2020-02-15 /pmc/articles/PMC6999184/ /pubmed/32063732 http://dx.doi.org/10.11613/BM.2020.010901 Text en Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Coskun, Abdurrahman
Ialongo, Cristiano
Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process
title Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process
title_full Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process
title_fullStr Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process
title_full_unstemmed Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process
title_short Six Sigma revisited: We need evidence to include a 1.5 SD shift in the extraanalytical phase of the total testing process
title_sort six sigma revisited: we need evidence to include a 1.5 sd shift in the extraanalytical phase of the total testing process
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999184/
https://www.ncbi.nlm.nih.gov/pubmed/32063732
http://dx.doi.org/10.11613/BM.2020.010901
work_keys_str_mv AT coskunabdurrahman sixsigmarevisitedweneedevidencetoincludea15sdshiftintheextraanalyticalphaseofthetotaltestingprocess
AT ialongocristiano sixsigmarevisitedweneedevidencetoincludea15sdshiftintheextraanalyticalphaseofthetotaltestingprocess